Soluble vascular endothelial growth factor in various blood transfusion components

Transfusion

Volumn 39, Issue 10, 1999, Pages 1078-1083

  Nielsen, Hans Jørgen ^a   Werther, K ^b   Mynster, T ^b   Brunner N ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE DERIVATIVE; GLUCOSE; MANNITOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULOTROPIN;

ARTICLE; BLOOD COMPONENT THERAPY; BLOOD STORAGE; BLOOD TRANSFUSION; CANCER GROWTH; CELL GRANULE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PROTEIN CONTENT;

BLOOD PLATELETS; BLOOD PRESERVATION; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR SPACE; FEMALE; HUMANS; LEUKAPHERESIS; LYMPHOKINES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOLUBILITY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032826960     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39101078.x     Document Type: Article

References (45)

1. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992;216:633-8.
2. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-8.
3. Blomberg J, Möller T, Olsson H, et al. Cancer morbidity in blood recipients-results of a cohort study. Eur J Cancer 1993;29A:2101-5.
4. Cerhan JR, Wallace RB, Folsom AR, et al. Transfusion history and cancer risk in older women. Ann Intern Med 1993;119:8-15.
5. Brandt L, Brandt J, Olsson H, et al. Blood transfusion as a risk factor for non-Hodgkin lymphoma. Br J Cancer 1996;73:1148-51.
6. Cerhan JR, Wallace RB, Folsom AR, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Institute 1997;89:314-8.
7. Nielsen HJ. Detrimental effects of perioperative blood transfusion. Br J Surg 1995;82:582-7.
8. Nielsen HJ. Clinical impact of bioactive substances in blood components. Implications for leucocyte filtration. Infusionsther Transfusionsmed 1998;25:296-304.
9. Ness PM, Walsh PC, Zahurak M, et al. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood. Transfusion 1992;32:31-6.
10. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
11. Hoh H, Umpleby H, Cooper A, Taylor I. Recurrence of colorectal cancer and perioperative blood transfusion. Is blood storage time important? Dis Colon Rectum 1990;33:127-30.
12. Mynster T, Dybkjær E, Kronborg G, Nielsen HJ. Immunomodulating effect of blood transfusion: is storage time important? Vox Sang 1998;74:176-81.
13. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996;275:150-4.
14. Frank RE, Saclarides TJ, Leurgans S, et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995;222:695-9.
15. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15:165-76.
16. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
17. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997;17:70-7.
18. Gaudry M, Bregerie O, Andrieu V, et al. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997;90:4153-61.
19. Iijima K, Yoshikawa N, Nakamura H. Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods 1996;196:199-209.
20. Harmey JH, Dimitriadis E, Kay E, et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1. Ann Surg Oncol 1998;5:271-8.
21. Neufeld G, Cohen T, Gitay-Goren H, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996;15:153-8.
22. Edvardsen L, Nielsen HJ, Pedersen AN, et al. Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates (letter). Eur J Haematol 1996;57:185-7.
23. Edvardsen L, Taaning E, Mynster T, et al. Bioactive substances in buffy-coat-derived platelet pools stored in platelet-additive solutions. Br J Haematol 1998;103:445-8.
24. Hammer JH, Mynster T, Reimert CM, et al. Reduction of bioactive substances in stored donor blood. Prestorage vs. bedside leucofiltration. Eur J Haematol 1999;63:29-34.
25. Nielsen HJ, Pappot H, Christensen IJ, et al. Association of plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998;316:829-30.
26. Nielsen HJ, Edvardsen L, Vangsgaard K, et al. Time-dependent histamine release from stored human blood products. Br J Surg 1996;83:257-62.
27. Nielsen HJ, Reimert CM, Pedersen AN, et al. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion 1996;36:960-5.
28. Muylle L, Joos M, Wouters E, et al. Increased tumor necrosis factor α (TNF α), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored plasma concentrates: relationship between TNF α and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33:195-9.
29. Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997;94:663-8.
30. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thrornb Haemost 1998;80:171-5.
31. Hammer JH, Mynster T, Reimert CM, et al. Effect of heating on extracellular bioactive substances in stored human blood: in vitro study. J Trauma 1997;43:799-803.
32. Oksanen K, Ebeling F, Kekomaki R, et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994;67:356-61.
33. Senger DR, van de Water L, Brown LF, et al. Vascular permeability factor (VPF/VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24.
34. Maniwa Y, Okada M, Ishii N, Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114:1668-75.
35. Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD. Effect of histamine on the growth of human gastrointestinal tumours: reversal by histamine. Gut 1993;34:1091-6.
36. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
37. Bajou K, Noel A, Gerard R, et al. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nature Med 1998;4:923-8.
38. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993;269:3024-9.
39. Webb NJ, Myers CR, Watson CJ, et al. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998;10:254-7.
40. Taichman NS, Young S, Cruchley AT, et al. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997;62:397-400.
41. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144-6.
42. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87.
43. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 1999;53:302-7.
44. Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998;58:1952-9.
45. Nielsen HJ, Hansen U, Christensen IJ, et al. Tumour-associated tissue eosinophilia and mastocytosis are independent prognostic variables in colorectal cancer. J Pathol (in press).